South Africa's Tutu out of hospital after treatment
- Wall St. rises amid robust GDP data, mixed earnings
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Archbishop Emeritus and Nobel Laureate Desmond Tutu in a file picture. REUTERS/Mark Wessels
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
CAPE TOWN (Reuters) - Retired South African cleric and anti-apartheid campaigner Archbishop Desmond Tutu was discharged from hospital on Wednesday, after he was re-admitted on Saturday to treat an infection, his family said.
The 84-year-old Nobel Peace Prize winner, who has been living with prostate cancer for nearly 20 years, was re-admitted to hospital to treat an infection following surgery this month.
Tutu, who has struggled with ill health in recent years, was admitted to hospital late last month and had surgery to remedy a recurring infection resulting from past treatment for prostate cancer, a statement by his family said without elaborating.
On Tuesday, Tutu's family told a media briefing that he was responding well to a new course of antibiotics, and denied social media reports that the cleric had died.
The former Anglican archbishop of Cape Town often used the pulpit to criticize white-minority rule, which ended in 1994, earning him international acclaim. He retired from public life in 2010 but has been outspoken on political issues.
(Writing by Tiisetso Motsoeneng; Editing by James Macharia)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Italy antitrust agency probes WhatsApp messaging service
- Flat profits as China's big banks clean up bad loans, margins slip
- Exclusive: Deutsche Bank among bidders for HSH Nordbank's debt portfolio
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!